Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

Tuba N. Gidea Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Faculty of Medicine and Health, The University of Sydney, Sydney, AustraliaView further author information

Elizabeth C. Pavera Melanoma Institute Australia, The University of Sydney, Sydney, Australia;d NSW Health Pathology, Sydney, AustraliaView further author information

Zarwa Yaseena Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, AustraliaView further author information

Nigel Mahera Melanoma Institute Australia, The University of Sydney, Sydney, Australia;c Faculty of Medicine and Health, The University of Sydney, Sydney, Australia;d NSW Health Pathology, Sydney, Australia;e Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, AustraliaView further author information

Nurudeen Adegokea Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Faculty of Medicine and Health, The University of Sydney, Sydney, AustraliaView further author information

Alexander M. Menziesa Melanoma Institute Australia, The University of Sydney, Sydney, Australia;c Faculty of Medicine and Health, The University of Sydney, Sydney, Australia;f Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia;g Department of Medical Oncology, Mater Hospital, Sydney, AustraliaView further author information

Ines Pires da Silvaa Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Faculty of Medicine and Health, The University of Sydney, Sydney, Australia;h Department of Medical Oncology, Blacktown and Westmead Hospitals, Sydney, AustraliaView further author information

James S. Wilmotta Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Faculty of Medicine and Health, The University of Sydney, Sydney, AustraliaView further author information

Georgina V. Longa Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Faculty of Medicine and Health, The University of Sydney, Sydney, Australia;f Department of Medical Oncology, Royal North Shore Hospital, Sydney, Australia;g Department of Medical Oncology, Mater Hospital, Sydney, AustraliaCorrespondence[email protected]

https://orcid.org/0000-0001-8894-3545 View further author information

Richard A. Scolyera Melanoma Institute Australia, The University of Sydney, Sydney, Australia;b Charles Perkins Centre, The University of Sydney, Sydney, Australia;c Faculty of Medicine and Health, The University of Sydney, Sydney, Australia;d NSW Health Pathology, Sydney, Australia;e Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, AustraliaView further author information

show all

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date